Gemphire sinks on Phase IIb gemcabene data in hypercholesterolemia

Gemphire Therapeutics Inc. (NASDAQ:GEMP) plummeted $8.73 (47%) to $9.93 on Monday after it reported preliminary Phase IIb data for its lead candidate gemcabene (CI-1027) to treat hypercholesterolemia in which

Read the full 295 word article

How to gain access

Continue reading with a
two-week free trial.